A man has died after being injured at the construction site where Everton FC are building their new stadium. The 26 year-old victim, a worker on the development, was involved in an “incident” at the Bramley Moore Dock site in Liverpool at around lunchtime. A Merseyside Police spokesperson said: “We can confirm that a man has died after an incident at Bramley Moore Dock this afternoon. At around 1pm it was reported that a man, aged 26, had been injured. “He was taken to hospital where he was pronounced dead. His next of kin have been told and an investigation is under way.” A spokesperson for the club said they were ‘heartbroken’ by the unnamed individual’s death. Everton FC said: “Everyone at Everton Football Club is heartbroken by the news a male worker has died following an incident at the Everton Stadium site at Bramley-Moore Dock. “The thoughts and condolences of everyone connected with Everton are with his family, friends, and colleagues at this unimaginably sad time. “Stadium contractor Laing O’Rourke has immediately launched an investigation and will work with the police and the Health and Safety Executive to establish the full details of the incident.” Work began on the new stadium two years ago, as part of a £500 million waterside scheme in the city. A spokesperson for contractors Laing O’Rourke said: “We can confirm that earlier today a member of our team, who was carrying out work for one of our sub-contractors, was seriously injured in an incident. He was taken to hospital via ambulance, where he sadly died. “We are shocked and saddened by today’s tragic incident and our thoughts are with the family and friends of the deceased man and our wider project team. “The police and the Health and Safety Executive are on site and we have suspended work until further notice. We will cooperate fully with any investigation that follows.” Read More Cook says Australian mushroom deaths were ‘accidental’: ‘I had no reason to hurt people I love’ Couple whose husky mauled their baby daughter to death allowed to keep pack of dogs Heartbreaking moment Hawaiian broadcaster reveals on air he lost four family members to Maui wildfires RAF jets launched to intercept Russian bombers off coast of UK Bibby Stockholm: A timeline of the government’s controversial migrant accommodation Public support for new Brexit referendum revealed

A nationwide outage struck Australia’s second-largest telecommunications company Optus on Wednesday, wreaking havoc at peak hour as millions

UPDATE: Jul. 12, 2023, 6:20 p.m. EDT This list has been updated with the best

Real Salt Lake kept their MLS Cup playoffs hopes alive with a narrow win over Houston Dynamo.

Apple on Thursday confirmed it is endorsing passage of a California law requiring major gadget makers to enable people to fix their devices without...

A new survey has found that nearly half of adults in the United States are interested in taking prescription drugs for weight loss, such as Ozempic or Wegovy. In a KFF health tracking poll published on 3 August, researchers reported that 45 per cent of adults said they’d be interested in taking a “safe and effective” prescription drug for weight loss. Meanwhile, seven in 10 adults said they’ve heard at least “a little” about a new class of drugs being used for weight loss, with about one in five saying they have heard “a lot” about these drugs. Ozempic is a type 2 diabetes medication known for its weight loss side effects. Similar semaglutide injections, such as Wegovy and Mounjaro, have been specifically approved for the treatment of obesity and weight loss. This class of drugs called GLP-1 agonists works by mimicking a hormone called glucagon-like peptide 1 (GLP-1), regulating blood sugar levels and slowing down the rate at which food leaves the stomach to create the feeling of fullness. Of the US adults surveyed, older groups were some of the most aware of prescription weight loss drugs, with 76 per cent being those who have been told by a doctor in the past five years that they are overweight or obese. Nearly 60 per cent of those surveyed said they were currently trying to lose weight as well. While there was an overall interest in taking a prescription weight loss drug, that interest significantly decreased when people were asked whether they would take the medication as a routine injection. Only 16 per cent of adults said they would still take Ozempic or Wegovy, even if it wasn’t covered by their health insurance and was not specifically approved by the US Food and Drug Administration for weight loss. In fact, most people believed that insurance companies should cover the cost of weight loss drugs for adults who are overweight or obese, with an overwhelming 80 per cent of adults. Additionally, a large majority of adults believed the substantial profits that pharmaceutical companies have made from increased demand for weight loss drugs is a major factor contributing to the cost of injections like Ozempic and Wegovy. According to Novo Nordisk, the pharmaceutical company behind these prescription drugs for diabetes and weight loss, the list price for Ozempic can cost $935.77 per month without health insurance. Although the majority of adults said they trust pharmaceutical companies like Novo Nordisk to provide “reliable information” about safety and side effects of GLP-1 agonists, only 22 per cent said they trust these companies to price their products fairly. The FDA has listed the most common side effects of taking Wegovy as nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, and digestive disorders. More serious complications can occur from use of Wegovy or Mounjaro, such as the “potential risk of thyroid C-cell tumours,” pancreatitis, gallbladder problems, acute kidney injury, increased heart rate, and suicidal behaviour or thinking. Taking Ozempic can also lead to possible thyroid tumours, including cancer, pancreatitis, changes in vision, and kidney and gallbladder problems. Recently, several patients reported suffering from severe gastroparesis, also known as stomach paralysis, after taking the prescription weight loss medications. In a report from CNN, two people claimed that their “stomachs are paralysed” after taking Ozempic. “I wish I never touched it. I wish I’d never heard of it in my life,” Joanie Knight, a 37-year-old from Louisiana, told CNN. “This medicine made my life hell. So much hell. It has cost me money. It cost me a lot of stress; it cost me days and nights and trips with my family. It’s cost me a lot, and it’s not worth it. The price is too high.” One woman was also diagnosed with cyclic vomiting syndrome, which causes her to throw up multiple times a day. “I’ve almost been off Ozempic for a year, but I’m still not back to my normal,” said Emily Wright, a 38-year-old teacher from Toronto. Shortly after the report, the FDA shared in a statement with The Independent that it has become aware of stomach paralysis occurring among patients taking the medications. “The FDA has received reports of gastroparesis with semaglutide and liraglutide, of which some documented the adverse event as not recovered after discontinuation of the respective product at the time of the report,” the agency said. However, officials clarified that they were unable to determine whether taking Ozempic or Wegovy was the cause of stomach paralysis, or if it was caused by a different issue. “Gastroparesis can be a complication of diabetes that is related to long-standing or poorly controlled disease, further complicating the ability to determine what role the drugs played in the reported events,” the FDA added. In response to reports of stomach paralysis, drug manufacturer Novo Nordisk noted that these medications have been used to treat type 2 diabetes “for more than 15 years”, and for the “treatment of obesity” for eight years. “Semaglutide has been extensively examined in robust clinical development programs, large real world evidence studies and has cumulatively over 9.5 million patient years of exposure,” a spokesperson for Novo Nordisk said in a statement to The Independent. “Gastrointestinal (GI) events are well-known side effects of the GLP-1 class. For semaglutide, the majority of GI side effects are mild to moderate in severity and of short duration. GLP-1’s are known to cause a delay in gastric emptying, as noted in the label of each of our GLP-1 RA medications. Symptoms of delayed gastric emptying, nausea and vomiting are listed as side effects.” Read More Obese people on weight-loss jabs ‘should be prepared to stay on them for life’ Ozempic users report stomach paralysis as weight loss drug side effect: ‘I wish I never touched it’ Sharon Osbourne says she was ‘nauseous’ for weeks after taking Ozempic to lose weight Sharon Osbourne reveals what Ozempic did to her when she was taking it Ozempic users report stomach paralysis as side effect: ‘I wish I never touched it’ Lorraine Candy: ‘Perimenopausal rage made me unravel’

Kylian Mbappe told Paris Saint-Germain on Monday that he would not be taking up an option to extend his contract until 2025, raising the spectre of him following Lionel Messi...

Led by 28 points from Nikola Jokic, the Denver Nuggets beat the Miami Heat 94-89 on Monday to

The NFL season is only one week old but there are already some players who signed new contracts during the offseason that have not panned out.

Monday Night Football has had some wild finishes in the early portion of the season. Which two teams are set to wrap up Week 7?

The Bloomberg Invest conference resumed Thursday with some of the most influential leaders in finance gathering in New

Canadian figure skater Alexandra Paul, a 2014 Olympic ice dancer and former national junior champion, has died at age...